Discover our top picks for must-attend sessions at the World EPA Congress 2025 in Amsterdam. Enhance your understanding of core topics with our recommended pre-reading materials
Read More
We are delighted to announce that Clare Foy (Director – Global Market Access), Hannah Palin (Director – Local Market Access), and Calum Jones (Associate Director – Health Economics) will be...
Read More
Global healthcare faces growing pressures. We explore how HEOR is evolving in 2025 to deliver value, meet payer needs, and support market access decisions.
Will Battershill and Hollie Wheat from Delta Hat discuss key insights into HTA decision-making from ISPOR Europe. Will explores the hot topic of incorporating patient and carer perspectives into decision-making, whilst Hollie dives into the use of surrogate endpoint evaluation in HTA decision-making.
Discover our tailored health economics training for Pharma and Medtech teams. Delivered by experts, it combines practical insights with real-world experience.
Challenges for orphan medicines entering the European market – Part 3: Economic evidence development
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and offer solutions that can help improve patient access. In Part 3 of...
Read More
We’re delighted to announce that we will be exhibiting at ISPOR Europe in Barcelona over the 18th–20th November 2024. Mtech Access experts will be joined by our colleagues from across Petauri, including...
Read More
How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison? In...
Read More
Evelyne Priestman who recently joned our Health Economics Team, shares what inspired her to join Mtech Access and her experiences since joining the team
Calum Jones (Associate Director – Health Economics) shares his experience speaking at the 2024 HTAi Conference. Calum participated in the panel discussion: ‘Surrogate Endpoints in Health Technology Assessment (HTA): From Trials to Economic Evaluations’.
